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Delivery of anticancer agents to solid tumors is not
well investigated and studies analyzing drug concen-
trations in human tumor tissue, especially in the brain,
are scarce.
In our institution, we have the opportunity to
directly measure anticancer drug concentrations in
glioblastoma (GBM) tumor tissue in correlation to
plasma concentration. GBM patients with a relapse,
however in good performance status are offered
secondary surgery where appropriate and participation
in a prospective trial with gefitinib [1]. Gefitinib is
currently under scrutiny for the treatment of high
grade glioma [2].
At least 5 days before re-operation, patients receive
gefitinib 500 mg daily continuously until tumor pro-
gression or intolerable side effects. Patients on
cytochrome P450 isoenzyme CYP3A4-inducing an-
tiepileptic drugs (EIAE) have to change to a non-
enzyme-inducing drug, due to predicted ensuing
interactions of EIAE with gefitinib metabolism,
reducing its systemic availability. The trial is approved
by the local ethic committee and is registered within
the National Library of Medicine Clinical Trials
Database (www.clinicaltrials.gov, NCT00250887).
Here we report on surprisingly high tumor tissue
levels of gefitinib from the first seven patients (Ta-
ble 1). Tumor tissue and blood samples were snap
frozen immediately upon removal and stored at –70C
for analysis (Laboratory Analytico Medinet B.V.,
Breda, NL). High performance liquid chromatography
coupled to tandem mass spectroscopy was per-
formed to determine drug concentrations, as described
previously [3].
To our knowledge this is the first consecutive series
of gefitinib concentrations in human brain tumor
tissue. We suggest, that higher drug exposure is not
required to treat glioma patients.
Further translational research will be performed
with the tumor material to correlate responding
patients to their tumor EGFR pathway activity and to
define molecular markers predictive for response.
Table 1 Gefitinib tumor and plasma concentrations
Pat. No. GBM tissue (ng/g) Plasma (ng/ml)
1* 24103 na
1* 8681 na
1* 11103 na
2 3132 247
3 4963 176
4 6218 181
5 2852 4
6 4730 127
7 3468 176
na: not assessed
*All three samples of this patient were collected on the same
occasion
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